SCHEMBL4923597

SCHEMBL4923597

Cc1nc(F)ccc1-c1cccc2c(N)c3c(nc12)CN(C1CCC1)C3=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.35
▸ PIK3CA P42336 2/20 0.33
▸ POLB P06746 2/20 0.32
▸ BMPR1A P36894 1/20 0.32
▸ ACVRL1 P37023 1/20 0.32
▸ ACVR1 Q04771 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ NPY1R P25929 1/20 0.32
▸ NPY5R Q15761 1/20 0.32
▸ ADRA1A P35348 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31
▸ GRM5 P41594 3/20 0.31
▸ CDK4 P11802 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SCN9A Q15858 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921007 0.90 MAPK1 (0.36) MAPK1POLBPARP1HTTESR2
SCHEMBL2669400 0.87 PIK3CA (0.35) PIK3CAPOLBBMPR1AACVRL1ACVR1
SCHEMBL2661491 0.87 MAPK1 (0.35) MAPK1POLBBMPR1AACVRL1ACVR1
SCHEMBL2660877 0.85 MAPK1 (0.43) MAPK1POLBPARP1HTTESR2
SCHEMBL2661432 0.85 MAPK1 (0.34) MAPK1PIK3CANPY1RNPY5RGRM5
SCHEMBL4921068 0.83 NPY1R (0.39) MAPK1POLBNPY1RNPY5RKCNH2
SCHEMBL2661112 0.83 BMPR1A (0.32) MAPK1PIK3CAPOLBBMPR1AACVRL1
SCHEMBL2661410 0.83 MEN1 (0.37) MAPK1PIK3CAPOLBBMPR1AACVRL1
SCHEMBL2669424 0.83 MAPK1 (0.36) MAPK1PIK3CAPOLBBMPR1AACVRL1
SCHEMBL2656990 0.83 MAPK1 (0.39) MAPK1NPY1RNPY5RGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF MAPK1 3191/4885PIK3CA 3396/4885POLB 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback